Differential regulation of release of acetylcholine in the striatum in mice following continuous exposure to selective D1 and D2 dopaminergic agonists.
The effect of continuously infusing the selective D1 and D2 dopamine receptor agonists, SKF 38393 and quinpirole, on the release of [3H]acetylcholine from prelabeled striatal slices was investigated. These biochemical parameters were correlated with the behavioral effects of these agonists. Acute injections of SKF 38393 or quinpirole did not affect either K(+)-stimulated or spontaneous release of [3H]acetylcholine. Chronic exposure to quinpirole reduced the K(+)-evoked release of [3H]acetylcholine by 25.7%; long-term treatment with SKF 38393 did not alter the release of [3H]acetylcholine, induced by K+ stimulation. Added in vitro, SKF 38393 increased the release of [3H]acetylcholine from striatal slices. The effect of the D1 dopamine receptor agonist, SKF 38393 was reduced after 7-days of infusion of SKF 38393 but was enhanced by 7-days of infusion of quinpirole. Activation of D2 dopamine receptors with quinpirole or of muscarinic receptors with carbachol induced an inhibition of release of [3H]acetylcholine. Chronic treatment with quinpirole diminished the response to the in vitro addition of quinpirole. The ability of carbachol to inhibit release of acetylcholine was not altered by continuous treatment with either SKF 38393 or quinpirole. Continuous infusion of SKF 38393 produced an initial grooming behavior; this behavior disappeared by 2 hr and remained absent during the 7 days of infusion of SKF 38393. Similarly, continuous administration of quinpirole produced stereotyped behavior, which peaked at 1 hr and disappeared by 4 hr and remained absent for the duration of the infusion. These findings demonstrate that continuous exposure to D1 or D2 agonists caused receptor-selective functional desensitization of D1 or D2 dopamine receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
Wang
H Y
HY
Department of Psychiatry, Medical College of Pennsylvania, Philadelphia 19129.
Zhou
L W
LW
Friedman
E
E
Weiss
B
B
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D015259:Dopamine Agents / Q000494:pharmacology*; D004873:Ergolines / Q000494:pharmacology; D006120:Grooming / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D019257:Quinpirole; D017447:Receptors, Dopamine D1 / Q000187:drug effects*; D017448:Receptors, Dopamine D2 / Q000187:drug effects*; D011976:Receptors, Muscarinic / Q000187:drug effects; D013239:Stereotyped Behavior / Q000187:drug effects
D015259:Dopamine Agents; D004873:Ergolines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D011976:Receptors, Muscarinic; D019257:Quinpirole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D002217:Carbachol; D000109:Acetylcholine